Abstract:Abstract Background: Platinum-based chemotherapy is the main choice of treatment for patients with advanced Non-small cell lung cancer (NSCLC). Platinum agents target DNA preferentially for cytotoxicity, which will lead to DNA damage and cell-cycle arrest. We hypothesize that genetic variations in cell cycle pathway may modulate response to platinum-based chemotherapy. In this study, we utilized a comprehensive pathway-based approach to identify genetic variations in the cell-cycle pathway as predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy. Material and Methods: We genotyped 633 polymorphisms from 105 cell cycle-related genes in 598 advanced NSCLC cases who received first-line platinum-based chemotherapy. All genotypes were analyzed for association with overall survival and evaluated for potential cumulative and gene-gene interactions that further modulated overall survival. Multiple statistic analyses were applied, including individual SNP analysis, cumulative genotype analysis, haplotype analysis, survival tree analysis and Kaplan-Meier survival analysis. Results: 65 SNPs from 40 cell-cycle genes were identified that were significantly associated with NSCLC overall survival (p<0.05) individually. We found that increasing numbers of potential high-risk alleles in any cell-cycle checkpoint would lead to increased risk of death. Compared with other checkpoints, G1/S checkpoint showed more significant associations with patients’ survival. For the combined analysis of unfavorable genotypes in G1/S checkpoint, compared with the referent group (≤20 unfavorable genotypes), the HRs for patients carrying 21-23 and 24-32 unfavorable genotypes were 1.94(95%CI 1.47-2.56) and 3.00(95%CI 2.33-3.85), respectively (p for trend < 0.0001), and also a significant reduction of median survival time from 24.05 to 9.18 months (log-rank p < 0.0001). Heplotype analysis revealed that a TP73 haplotype (GTGTTA) was significantly associated with increased risk of death (p=0.00026). Survival tree analysis of overall cell-cycle pathway indicated G1/S checkpoint genes categorized patients into subgroups with different survival pattern. Conclusions: These results suggest that G1 and G1/S checkpoint genetic variations affect survival of advanced NSCLC patients treated with platinum-based chemotherapy and that there are gene-dosage effect and gene-gene interactions in modulating clinical outcomes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4662.

Abstract LB-316: Association of Bcl2 Family Gene Polymorphisms with Response to and Toxicity of Platinum-Based Chemotherapy in Non-Small-cell Lung Cancer Patients in a Chinese Population

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Genetic Variants of BCL2 Gene Predict Clinical Outcomes of Non-Small-cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy in a Chinese Population.

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Association between BCL-2 (-938C>A) polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated patients with advanced non-small cell lung cancer

A pharmacogenetics study of platinum- based chemotherapy in lung cancer: <i>ABCG2</i> polymorphism and its genetic interaction with <i>SLC31A1</i> are associated with response and survival

Abstract 4662: Genetic Variations in the Cell-Cycle Pathway and Survival of Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Association Of Base Excision Repair Gene Polymorphisms With Response To Chemotherapy Of Advanced Non Small-Cell Lung Cancer In A Chinese Population.

Gene-gene and Gene-Environment Interactions Influence Platinum-Based Chemotherapy Response and Toxicity in Non-Small Cell Lung Cancer Patients

Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients

Associations of genetic polymorphisms of the transporters organic cation transporter 2 ( OCT2 ), multidrug and toxin extrusion 1 ( MATE1 ), and ATP-binding cassette subfamily C member 2 ( ABCC2 ) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

Influence of single nucleotide polymorphisms in ABCB 1 , ABCG 2 and ABCC 2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer

Pharmacogenomics of Platinum-Based Chemotherapy Response in Nsclc: A Genotyping Study and A Pooled Analysis

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients.